revenue of of year. an everyone. Earlier fourth today, Thank announced over quarter you, quarter the increase we morning, million, and XXXX last fourth $XX.X XX% from good
$X.XX GAAP income of and non-GAAP reported share of diluted $X.XX also per diluted income share. net net per We
of very pleased business. our strength demonstrate and are underlying they with We the believe results these
These our From customers company back CE monitor, ship regulatory reduced another which Mark as for to the use all in XXX(k) our product competitiveness other letter, by us the increased for patient SpOX looking our the FDA the neonatal of the a claims receiving use orders the risk our made closing for for monitor, of proud and then I our in out our few increases signs patient include perspective, of warning am XXXX, the competitiveness. company. announced the achievements marketplace. a renewing and on and patiently of clearance COX and Now achievements decline FDA waited allowing October; competing to monitor patient expanding devices; for to vital the features throughout
regulatory revenue fourth the testament XX% full the a audits, to we over successfully addition commitment quarter and these perspective, over delivered a to year last is several XX% with our team increase which completed over a increase XXXX. compared a From achievements, In to record year our sales quality. to
record a our period achieved orders in for excess of XXXX in fourth high orders. also and first million We during the new quarter marked $XX
All CE was of our all we not achieved in sell during for patient monitor of could XXXX. nearly time when Mark a actively countries this
their orders XXXX considered cancel our to Mark, time, this a are and able were our we for our tender CE not without have first any not dynamic guidance. European in customers during we that in monitor While processes did quarter we encouraged this compete financial
have the a Succeeding leadership leader a Brent build Brent standard from Additionally, establishing growth a decision success is history medical new sales to sales care. to forward look delivering proven organization of is we continuing Johnson’s products a achieved. resulting who the when MaryBeth’s as MaryBeth technology We recently with in leadership Smith, announced of change we retire. upon and to
is discussion note. the Now to to XXXX, last to shifting one there prior item
We are work. with health remain not the return questions located we in to this event. a At this how and received impacted time, in coronavirus impacting them our China wish regarding and communication speedy good IRadimed. have is suppliers by We significantly
to update circumstances and monitor We will this you continue situation should change.
leverage I portfolio discussed tremendous knowledge last overcoming quarter and that our we that scalability that key the as the context priorities think potential the about deep environment. for product I current is of strength IRadimed believe I of MRI has challenges and and of in XXXX. our It initiatives
to MRI IV our initiatives priorities in revenue pump our share rates MRI and and growth our through and gaining First, is of patient list monitor. drive adoption higher market innovation for
launching second of detection ferromagnetic system on during FMD XXXX. the half or plan also the We
and XXX(k) our For longer-term plan on value mid-year. creation the IV to make pump still progress significant next-generation at acceleration, and submit to we continue
to to and technical needed education to Second, plans, support. sensibly commitment clinical growth our continuing infrastructure we plan support quality, invest while in our the
Third, and our productivity commercial strong and patient previously competitor. sole-sourced manager we leveraging focus and continue on with expect contracts were to GPO IDN recent footprint after considering especially adding gains, our a to monitor sales that successes our
external about team we can commercial exploring opportunistic further our expertise. leverage our we technical and be where Additionally, technologies will
look to markets in additional accelerate have value I deliver technologies and we regional that by we Finally, to providing targeted novel significant growth clinicians believe international support. patients.
intend patients that or of requiring of unique products higher care. Our while challenges products continue signs and innovative in environment infusion are the critically facilitate delivering create driving MRI vital accurate standard and sedation, awareness developing monitoring. eliminating MRI a project and tiles ill who to access risk the We the for of
for Now, full I our year the quickly will summarize first XXXX. and quarter financial the guidance
$XX.X $X.XX. to share XXXX, year to report earnings full $X.XX expect $X.XX revenue and per earnings diluted to of we million, diluted million the GAAP $X.XX non-GAAP of to $XX.X For of
forecasted tax effective guidance which the to impacts XXXX, full We our negatively are expecting results. XXXX to the XXXX of comparison higher earnings year compared rate during XXXX a
to $X.XX share non-GAAP $X.XX. million, first we revenue $XX.X of earnings share $XX.X per expect to and quarter XXXX, the of million $X.XX For $X.XX of diluted earnings GAAP per to
to includes renew monitor impact needed of mentioned, time our in previously CE revenue processes not guidance quarter during to first being participate expected patient Mark. As the our the tender any able
a now discussion will Brent I call the organization. sales to turn of the for over